SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Akanda Corp. is a cannabis cultivation, manufacturing, and distribution company, which engages in the provision of premium quality and ethically sourced medical cannabis products to patients. The company cultivates and processes natural cannabis at facilities in the Kingdom of Lesotho, Africa and intend to supply medicinal-grade cannabis biomass, cannabis flower, and cannabis concentrates to wholesalers. It also imports and sells medical cannabis-based products. The company was founded on July 16, 2021 and is headquartered in New Romney, the United Kingdom.

Akanda Corp

Akanda Corp is experiencing a parabolic rally driven by its extremely low float and intense short-squeeze dynamics, with traders heavily focused on the stock's lack of available shares to borrow and astronomical borrow rates. While bulls are celebrating life-changing gains and pushing for triple-digit targets, many community members are expressing caution, citing the company's history of frequent reverse splits and ongoing dilution concerns as red flags.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk is experiencing significant volatility as investors react to a massive earnings beat and strong forward guidance by engaging in profit-taking after a historic year-long rally. The community is sharply divided, with bulls pointing to the company's robust AI-driven data center growth and share buyback program as proof of long-term value, while bears are focused on potential overvaluation and the risk of a broader cyclical slowdown in the memory sector.

The White Alien has arrived. The countdown to domination starts now.

The White Alien

The White Alien is generating buzz through aggressive social media cross-promotion with various other memecoins, sparking intense community debate between optimistic traders betting on rapid price momentum and skeptics questioning the token's long-term legitimacy.

Atlassian Corp. is a holding company, which engages in providing team collaboration and productivity software. Its products include Jira Software, Confluence, Jira Service Management, and Loom. The company was founded by Michael Cannon-Brookes and Scott Farquhar in October 2002 and is headquartered in San Francisco, CA.

Atlassian Corporation - Ordinary Shares - Class A

Atlassian Corporation Plc

Atlassian is trending following a double earnings beat that topped analyst expectations, signaling a potential sentiment shift for the broader SaaS sector. While some community members are skeptical of a lasting turnaround, many are actively discussing a rotation back into high-growth software as the company leans into AI integration to drive future revenue.

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of immunotherapies to treat cancer and autoimmune diseases. Its products include CUE-400 series (autoimmune diseases), CUE-500 series (targeted cell depletion), and CUE-100 series (Oncology). The company was founded by Ronald D. Seidel III, Steven Almo, and Rodolfo Chaparro on December 31, 2014 and is headquartered in Boston, MA.

Cue Biopharma Inc

Cue Biopharma is currently experiencing extreme volatility and heavy volume as traders react to a recent preclinical milestone payment and an upcoming R&D presentation, while others express deep skepticism regarding the company's long-term performance and potential reverse split. The community is sharply divided, with bulls pointing to fundamental technology developments and Big Pharma partnerships, while bears highlight persistent dilution, management concerns, and a downward trend in share price.

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Terra Luna Classic is trending due to community anticipation surrounding the latest monthly Binance token burn, which investors believe will reduce supply and drive upward price momentum. Proponents are actively discussing long-term recovery goals and the potential for a supply shock, while skeptical traders continue to debate the project's viability following its historic market collapse.

NEOS ETF Trust - NEOS Nasdaq 100 High Income ETF

NEOS Nasdaq 100 High Income ETF

Investors are actively debating the merits of the NEOS Nasdaq 100 High Income ETF (QQQI), frequently comparing its tax-efficient return-of-capital structure and monthly distribution reliability against other income-focused holdings like JEPQ, SPYI, and SCHD. The community is focused on evaluating these ETFs as long-term income generators for retirement, with a particular emphasis on whether their covered call strategies provide better risk-adjusted returns and capital preservation compared to traditional growth indices.

iShares Bitcoin Trust ETF (The) - iShares Bitcoin Trust Beneficial Interest

iShares Bitcoin ETF

IBIT is currently trending as investors weigh mixed chart signals against robust institutional inflows, with the community actively debating whether to treat the asset as a bottoming opportunity or a risk-heavy proxy prone to volatility. Discussions are centered on critical technical thresholds, option market positioning, and the broader impact of institutional accumulation on Bitcoin's long-term price trajectory.

Alchemy Pay

Alchemy Pay is capturing significant community attention as investors debate its transition toward a Layer 1 blockchain and expansion of its fiat-to-crypto payment infrastructure. While some traders are bullish on new regulatory licensing and upcoming mainnet developments, others are actively debating concerns regarding token supply inflation and the project's long-term competitive moat against other payment solutions.

Salesforce, Inc. engages in the design and development of cloud-based enterprise software for customer relationship management. Its solutions include sales force automation, customer service and support, marketing automation, digital commerce, community management, collaboration, industry-specific solutions, and salesforce platform. The firm also provides guidance, support, training, and advisory services. The company was founded by Marc Russell Benioff and Parker Harris in 1999 and is headquartered in San Francisco, CA.

Salesforce Inc

Salesforce is trending as the stock undergoes a sharp re-rating alongside the broader software sector, with community discourse dominated by the 'SaaSpocalypse' narrative and conflicting views on whether AI serves as a long-term catalyst or an existential threat to its core business. Investors are closely monitoring the impact of aggressive share buybacks against shifting sentiment as the stock tests significant support levels amid heavy volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

NeuroPace to Report First Quarter 2026 Financial Results on May 12, 2026

NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the first quarter of...

NeuroPace Highlights Expanding Clinical Evidence Leadership with Published 3-Year Post-Approval Study (PAS) Results in Neurology and NAUTILUS Presentation at AAN 2026

NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with drug resistant epilepsy, today announced a major milestone in its clinical evidence...

NeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Shares of NeuroPace, Inc. (NASDAQ:NPCE - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the eight ratings firms that are currently covering the company, MarketBeat...

NeuroPace to Present at the 25th Annual Needham Virtual Healthcare Conference

NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will present at the 25th Annual...

NeuroPace (NPCE) Up 0.9% Since Last Earnings Report: Can It Continue?

NeuroPace (NPCE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Add NeuroPace Stock to Your Portfolio Now

NPCE rides strong RNS adoption and AI innovation, but near-term profitability faces pressure as IGE expansion and revenue contribution remain uncertain.

Wall Street Analysts See a 41.29% Upside in NeuroPace (NPCE): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 41.3% in NeuroPace (NPCE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

NeuroPace (NASDAQ:NPCE) Upgraded at Wells Fargo & Company

Wells Fargo & Company upgraded shares of NeuroPace to a "strong-buy" rating in a research report on Wednesday...

NeuroPace (NASDAQ:NPCE) Stock Rating Lowered by Wall Street Zen

Wall Street Zen cut NeuroPace from a "buy" rating to a "hold" rating in a research note on Sunday...

Key Catalysts That Will Likely Drive Prospects for NPCE Stock in 2026

NPCE heads into 2026 with 20%+ RNS growth targets, higher Medicare reimbursement and a cleaner revenue mix as the DIXI distribution business rolls off.

NeuroPace, Inc. develops, manufactures, and markets implantable devices for treating epilepsy and neurological disorders. It offers implantable components, which include the RNS neurostimulator as well as depth and cortical strip leads. The firm's RNS System is designed for the treatment of medically refractory partial epilepsy and includes implantable and external products. The company was founded by Rebecca L. Kuhn, Frank M. Fischer on November 19, 1997 and is headquartered in Mountain View, CA.

NPCE
NeuroPace Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest NPCE News

NPCENeuroPace Inc